Lupin Ltd Share Price
(LUPIN)
₹2068.75
as on 04:01PM, 25 Mar 2025
Lupin Performance
Day's Low
Day's High
₹2,053.85Day's Price Range₹2,12552 Week's Low
52 Week's High
₹1,493.352-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | + 11.62 % |
| 3 Month Return | -2.85 % |
| 1 Year Return | + 31.27 % |
| Market Stats | |
| Previous Close | ₹2,119.95 |
| Open | ₹2,120.15 |
| Volume | 7.02L |
| Upper Circuit | ₹2,331.90 |
| Lower Circuit | ₹1,907.95 |
| Market Cap | ₹96,784.40Cr |
Lupin Fundamentals
P/E Ratio
33.69
PEG Ratio
1.43
Market Cap
₹96,784.40 Cr
P/B Ratio
3.58
EPS
42.47
Dividend Yield
0.49
Sector
Pharmaceuticals
ROE
11.92
Mutual Fund Holdings of Lupin
Lupin Analyst Rating
based on 36 analysts
58.33%
Buy
30.56%
Hold
11.11%
Sell
Based on 36 analysts offering long term price targets for Lupin. An average target of ₹2296.19
Source: S&P Global Market Intelligence
Lupin Share analysis
Lupin price forecast by 36 analysts
Upside of8.31%
High
₹2800
Target
₹2296.19
Low
₹1834
Lupin target price ₹2296.19, a slight upside of 8.31% compared to current price of ₹2068.75. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:34.80%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:111.66%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Lupin Ltd
Lupin Stock Experiences Bullish Signals and Decline - 25 Mar, 2025
Lupin Ltd shows bullish momentum with a target price of ₹2,284 and strong support at ₹1,985. However, the stock fell by 3.2% to ₹2,054, indicating volatility.Lupin Digital Health Launches Cardiac Care Guide - 22 Mar, 2025
Lupin Digital Health has introduced a comprehensive Post-Procedure Home-Based Care Guide for cardiac patients, developed with the American College of Cardiology, to enhance recovery and reduce hospital readmissions.Lupin's Subsidiary Wins Prestigious CMO Award - 21 Mar, 2025
Nanomi B.V., a subsidiary of Lupin Limited, has been awarded the CMO Award for Life Science Leadership in Drug Delivery during the DCAT week in New York.Lupin Gains USFDA Approval for Amifampridine Tablets - 17 Mar, 2025
Lupin Ltd received tentative approval from the USFDA for Amifampridine Tablets, allowing entry into the market for treating Lambert-Eaton myasthenic syndrome. This approval strengthens Lupin's manufacturing capabilities and expands its portfolio in key therapeutic areas, with significant market potential indicated by Firdapse's $306 million sales in 2024.Lupin Faces Challenges Amid Tariff Threats - 11 Mar, 2025
Lupin Ltd's recent product launches, including a generic Xarelto, are overshadowed by potential US tariffs on pharma products. Despite strong financial performance and growth plans, the stock has declined 15% in 2025 due to tariff uncertainties and competitive pressures.Lupin Launches Rivaroxaban, IPA Proposes Tariff Changes - 07 Mar, 2025
Lupin Limited has launched Rivaroxaban Tablets USP, 2.5 mg in the US, a generic equivalent of Xarelto, following FDA approval. The Indian Pharmaceutical Alliance also proposed zero tariffs for US pharma imports, potentially benefiting the industry.Lupin Ltd Continues Upward Trend for Fifth Session - 06 Mar, 2025
Lupin Ltd's stock rose 0.59% to Rs 2022, marking its fifth consecutive gain. Over the past year, it has increased by 21.1%, outperforming both NIFTY and Nifty Pharma indices. However, it has seen an 8.14% decline in the last month.Citi Upgrades Lupin, Boosts Target Price Significantly - 05 Mar, 2025
Lupin shares surged after Citi upgraded its rating to buy and increased the target price to ₹2,260, driven by strong US sales and margin expectations. Despite potential tariff risks, Citi remains optimistic about Lupin's growth trajectory.Lupin Upgraded Amid Strong US Market Prospects - 04 Mar, 2025
Equirus has upgraded Lupin to a Long rating with a target price of Rs 2,379, highlighting strong launch momentum in the US and stable earnings outlook until FY27E. Jefferies maintains a Hold rating, noting Lupin's market share gains in Mirabegron and Spiriva, despite concerns about FY26.Concerns Over Proposed Tariff on Indian Pharmaceuticals - 03 Mar, 2025
The proposed 25% tariff on Indian pharmaceutical exports to the US raises concerns about drug affordability and supply chains, as outlined by Lupin's CFO. The Indian pharmaceutical industry is prepared to navigate these challenges, with Lupin's stock rising nearly 16% over the past year.Lupin Shares Surge Amid FDA Approval and Sustainability Rating - 24 Feb, 2025
Lupin Ltd experienced a share price surge following the FDA's Establishment Inspection Report for its Somerset facility. Additionally, the company received an 'A-' sustainability rating from CDP, highlighting its commitment to environmental practices. However, an analyst suggested a sell recommendation due to a weak stock structure.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 1 month, LUPIN stock has moved up by 11.6%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.89% to 16.92% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 21.50% to 22.04% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 74.3% return, outperforming this stock by 43.0%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.96% to 46.95% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.44% to 6.26% in Dec 2024 quarter
Lupin Financials
Lupin Index Inclusions
Lupin Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.95% | ||
| Foreign Institutions | 22.04% | 2.52 | |
| Mutual Funds | 16.92% | 0.20 | |
| Retail Investors | 6.26% | ||
| Others | 7.82% |
Lupin Key Indicators
Lupin Valuation
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (33.69x)
March 24, 2025
Industry (53.98x)
March 24, 2025
Highest (517.33x)
December 2, 2022
Lupin Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.58%.
Read More about Dividends
Lupin Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bullish trading position according to technical analysis indicators.
Lupin Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹96,784.40 Cr | 54.84% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹13,435.59 Cr | -0.8% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹70,875.13 Cr | 52.51% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹92,945.83 Cr | 50.06% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹66,028.64 Cr | 23.66% | 0.53 | NA | NA |
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,618.56Cr as on December 2024 (Q4 24)
Net Profit: ₹858.86Cr as on December 2024 (Q4 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Lupin Ltd
What is Lupin Ltd price today?
Lupin Ltd share price today stands at ₹2068.75, Open: ₹2120.15, Previous Close: ₹2119.95, High: ₹2125, Low: ₹2053.85, 52 Week High: ₹2402.9, 52 Week Low: ₹1493.3.
How to Buy Lupin Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Lupin Ltd shares
What are today's traded volumes of Lupin Ltd?
Today's traded volume of Lupin Ltd(LUPIN) is 7.02L.
What is today's market capitalisation of Lupin Ltd?
Today's market capitalisation of Lupin Ltd(LUPIN) is ₹96784.4Cr.
What is the 52 Week High and Low Range of Lupin Ltd?
How much percentage Lupin Ltd is down from its 52 Week High?
Lupin Ltd (LUPIN) share price is ₹2068.75. It is down -13.91% from its 52 Week High price of ₹2402.9
How much percentage Lupin Ltd is up from its 52 Week low?
Lupin Ltd (LUPIN) share price is ₹2068.75. It is up 38.54% from its 52 Week Low price of ₹1493.3